This bill would exempt certain oral medications from Medicare Part D's manufacturer discount program. Specifically, it targets drugs that have received FDA approval as new drugs and have been granted a special narrow exception by Medicare officials allowing them to be reclassified as non-innovator drugs under Medicaid's rebate program. The change would affect Medicare beneficiaries who take these particular medications, as well as pharmaceutical manufacturers of these drugs. The bill does not specify any new funding requirements or implementation timelines. It was introduced in December 2024 and referred to the House Committees on Energy and Commerce and Ways and Means for consideration.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.